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Abstract
Introduction: Smoking is a major cause of disease burden and reduced quality of life for people with
severe mental illness (SMI). It places significant resource pressure on health systems and financial stress
on smokers with SMI (SSMI). Telephone-based smoking cessation interventions have been shown to be
cost effective in general populations. However, evidence suggests that SSMI are less likely to be referred
to quitlines, and little is known about the effectiveness and cost effectiveness of such interventions that
specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking cessation
support for SSMI aims to bridge this gap. This paper describes the protocol for evaluating the cost
effectiveness of Quitlink.
Methods: Quitlink will be implemented in the Australian setting, utilizing the existing mental health peer
workforce to link SSMI to a tailored quitline service. The effectiveness of Quitlink will be evaluated in a
clustered randomized controlled trial. A cost-effectiveness evaluation will be conducted alongside the
Quitlink clustered randomized controlled trial (RCT) with incremental cost-effectiveness ratios (ICERs)
calculated for the cost (AUD) per successful quit and quality adjusted life year (QALY) gained at 8 months
compared with usual care from both health care system and limited societal perspectives. Financial
implications for study participants will also be investigated. A modeled cost-effectiveness analysis will
also be conducted to estimate future costs and benefits associated with any treatment effect observed
during the trial. Results will be extrapolated to estimate the cost effectiveness of rolling out Quitlink
nationally. Sensitivity analyses will be undertaken to assess the impact on results from plausible
variations in all modeled variables.
Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer worker and quitline
workforces and tailors quitline support specifically to provide that increased cessation support. Given
Quitlink engages these existing skilled workforces, it is hypothesized that, if found to be effective, it will
also be found to be both cost effective and scalable. This protocol describes the economic evaluation of
Quitlink that will assess these hypotheses.
Ethics and dissemination: Full ethics clearances have been received for the methods described below
from the University of Newcastle (Australia) Human Research Ethics Committee (H-2018-0192) and St
Vincent's Hospital, Melbourne (HREC/18/SVHM/154). The trial has been registered with the Australian
and New Zealand Clinical Trials Registry (ACTRN12619000244101). Participant consent is sought both to
participate in the study and to have the study data linked to routine health administrative data on publicly
subsidized health service and pharmaceutical use, specifically the Medicare Benefits and Pharmaceutical
Benefits Schemes (MBS/PBS). Trial findings (including economic evaluation) will be published in peer
reviewed journals and presented at international conferences. Collected data and analyses will be made
available in accordance with journal policies and study ethics approvals. Results will be presented to
relevant government authorities with an interest in cost effectiveness of these types of interventions.
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Introduction: Smoking is a major cause of disease burden and reduced quality of life for
people with severe mental illness (SMI). It places significant resource pressure on health
systems and financial stress on smokers with SMI (SSMI). Telephone-based smoking
cessation interventions have been shown to be cost effective in general populations.
However, evidence suggests that SSMI are less likely to be referred to quitlines, and
little is known about the effectiveness and cost effectiveness of such interventions that
specifically target SSMI. The Quitlink randomized controlled trial for accessible smoking
cessation support for SSMI aims to bridge this gap. This paper describes the protocol for
evaluating the cost effectiveness of Quitlink.
Methods: Quitlink will be implemented in the Australian setting, utilizing the existing
mental health peer workforce to link SSMI to a tailored quitline service. The effectiveness
of Quitlink will be evaluated in a clustered randomized controlled trial. A cost-effectiveness
evaluation will be conducted alongside the Quitlink clustered randomized controlled trial
(RCT) with incremental cost-effectiveness ratios (ICERs) calculated for the cost (AUD)
per successful quit and quality adjusted life year (QALY) gained at 8 months compared
with usual care from both health care system and limited societal perspectives. Financial
implications for study participants will also be investigated. A modeled cost-effectiveness
analysis will also be conducted to estimate future costs and benefits associated with any
treatment effect observed during the trial. Results will be extrapolated to estimate the cost
effectiveness of rolling out Quitlink nationally. Sensitivity analyses will be undertaken to
assess the impact on results from plausible variations in all modeled variables.
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Discussion: SSMI require additional support to quit. Quitlink utilizes existing peer
worker and quitline workforces and tailors quitline support specifically to provide that
increased cessation support. Given Quitlink engages these existing skilled workforces, it
is hypothesized that, if found to be effective, it will also be found to be both cost effective
and scalable. This protocol describes the economic evaluation of Quitlink that will assess
these hypotheses.
Ethics and dissemination: Full ethics clearances have been received for the methods
described below from the University of Newcastle (Australia) Human Research Ethics
Committee (H-2018-0192) and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154).
The trial has been registered with the Australian and New Zealand Clinical Trials Registry
(ACTRN12619000244101). Participant consent is sought both to participate in the
study and to have the study data linked to routine health administrative data on publicly
subsidized health service and pharmaceutical use, specifically the Medicare Benefits
and Pharmaceutical Benefits Schemes (MBS/PBS). Trial findings (including economic
evaluation) will be published in peer reviewed journals and presented at international
conferences. Collected data and analyses will be made available in accordance with journal
policies and study ethics approvals. Results will be presented to relevant government
authorities with an interest in cost effectiveness of these types of interventions.
Keywords: smoking, smoking cessation, mental illness, quitline, peer worker, economic evaluation,
cost-effectiveness

INTRODUCTION

compared to smokers without mental illness, the additional cost
of health care, lost productivity, carer costs, cigarette expenditure,
and other costs associated with observed heavier levels of smoking
among ~1.25 million smokers with mental illness (not just SMI),
was around AUD3.5 billion annually (or about AUD4.5 billion
in 20181) (13). This is in addition to expected costs if smokers
with mental illness smoked at similar levels to smokers with no
mental illness—the main cost drivers being productivity losses
(63%), health costs (12%), and cigarette expenditure (12%) (13).
In the 2009/2010 UK financial year, it was estimated that the costs
associated with smoking-related health care treatment, workrelated absenteeism, and premature mortality among people with
SMI was £2.3 billion (or about £3 billion in 20182) (14).
Numerous smoking cessation strategies have been shown to be
both effective and cost effective in the general population (15, 16).
However, smokers with severe mental illness (SSMI) report lower
cessation rates, in part attributable to higher levels of nicotine
dependence, and they are likely to benefit from more intensive
or extended interventions tailored to their needs (17). SSMI also
report a lack of encouragement to quit by health professionals,
who often mistakenly believe that people with mental illness
are not interested in quitting and that it will interfere with their
mental health recovery (12, 18).
Given the significant disease burden caused by smoking
among people with SMI, improving access to smoking cessation
interventions—and ensuring they are effective for SSMI—is

While smoking rates have declined in many countries, the rate
of decline among people living with severe and enduring mental
illness (SMI) has been significantly slower (1, 2). For example, in
the USA, over the period 2004–2011, smoking among individuals
with no mental illness declined from 19.5% to 15.6% (p < 0.001),
compared with 28.8% to 27.0% (p = 0.006) among individuals
living with mental illness (2). Smoking rates in people living with
SMI have been found to be around double the general population
and up to four times higher for those living with bipolar disorder
or schizophrenia (1, 3, 4). Smoking increases the risk of a number
of tobacco-related illnesses, including lung, throat and bowel
cancers, stroke, chronic obstructive pulmonary disease (COPD),
and myocardial infarction (5). Consequently, smoking is the
leading cause of preventable death among people living with
SMI—significantly shortening their life expectancy compared
to the general population and accounting for almost half of all
smoking-related deaths (4, 6–9).
Smoking-related conditions also cause significant morbidity
and reduce the quality of life of affected people, with or without
the presence of SMI (5, 10). Exacerbating this for people
living with SMI, smoking has been associated with increased
psychiatric symptoms and hospitalizations, as well as a
requirement for higher psychiatric medication dosages because
smoking accelerates the metabolism of some antidepressant and
antipsychotic medications (11, 12).
Data on the economic burden associated with smoking
in people with SMI are limited, but evidence suggests that it is
significant. In Australia in 2007, it was estimated, that when
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a vital health priority for this target group. Telephone-based
smoking cessation counseling services (such as quitlines) are
helpful for many smokers, but SSMI are infrequently referred to
such services by mental health practitioners as it is uncommon
for smoking cessation to be included in mental health planning
(19). This has led to the development of Quitlink—a randomized
controlled trial (RCT) of peer worker facilitated quitline support
for smokers with mental health problems, implemented in an
Australian setting (20). It aims to coordinate and enhance the
services of Quitline Victoria and engage mental health peer
workers to bridge the persistent gap between mental health
services and Quitline. The primary aim of the intervention is to
help SSMI quit smoking. Secondary aims include assessment of
the extent to which Quitlink improves health-related quality of
life (HRQoL) and reduces the burden on the health care system
in both the short and longer terms.
Examining the cost effectiveness of proven or potentially
effective interventions is increasingly important for public sector
funding decisions and priority setting (21, 22). Telephone-based
counseling interventions with or without complementary nicotine
replacement therapy (NRT) can be a relatively cost-effective way
to achieve smoking abstinence in general populations in both
upper and lower income country settings (16). Furthermore,
modeling suggests such interventions may even be cost saving
from a health care system perspective due to cost offsets resulting
from prevented health costs in the future (23–26).
While it has been well established that telephone-based
counseling interventions (with or without NRT) can be a very
cost-effective strategy for improving health and extending lives
(15, 16), there is little evidence regarding the cost effectiveness
of any smoking cessation strategies specifically targeting SSMI
(27). Barnett et al. (28) compared a cessation program (including
psychological counseling, NRT, and bupropion) given in an
outpatient care setting in the USA for smokers with depression
measured against a brief care comparator. After 18 months,
the intervention group had a 5.5% increased chance of ceasing
smoking (p < 0.05) at a cost of USD11,496 per successful quit
and USD9,580 per life year gained, concluding that it was a
relatively cost-effective intervention in the short run. In a more
recent RCT, Barnett et al. (29) found a stage-based intervention
(including computer-based assessment, regular feedback, face to
face sessions, and up to 10 weeks of NRT) initiated with people
during a psychiatric hospitalization, was highly cost effective.
The intervention achieved around a 12 percentage point increase
in smoking abstinence after 18 months compared with usual care
[18.8% abstinence in the intervention arm versus 6.8% abstinence
in usual care (p < 0.05)] at an estimated USD428 per additional
quality adjusted life year (QALY) gained when modeled over the
life course of participants. Rejas-Gutiérrez et al. (30) constructed
a model to estimate the budgetary impact for the Spanish health
care system from funding varenicline, bupropion, and NRT
combined with medical follow-up and counseling for people
with a major depressive disorder. They estimated that the cost of
funding such interventions (€25.3 million) was offset by health
costs avoided (€26.5 million) after 5 years, suggesting that cost
offsets for the health care system might increase over a longer
time period (30).

Frontiers in Psychiatry | www.frontiersin.org

The Quitlink intervention will utilize existing and skilled
Quitline and mental health peer workers. The peer workforce is
developing in Australia and internationally, working alongside
clinical staff to provide support based on shared lived experience
of mental illness and recovery (31). In Australia, quitlines are
government-funded services providing smoking cessation
counseling across each state and territory. In addition, in the
Australian setting, some of the medications to aid smoking
cessation are currently subsidized. The presence of these
funded health resources suggests that the additional resources
required to implement Quitlink would be relatively modest. It is
hypothesized then that, if effective, it is likely to be a highly costeffective intervention, which can feasibly be scaled up beyond
the trial setting. Such a priori expectations make the case for
a rigorous economic evaluation to be conducted alongside the
Quitlink RCT. This paper presents a protocol for the economic
evaluation of the Quitlink intervention to address the following
research question:
From the Australian health care system and limited societal
perspectives, what is the cost effectiveness of the Quitlink
intervention to increase smoking cessation and QALYs among
people living with SMI when compared with usual care?

THE QUITLINK TRIAL
Study Design

Quitlink is a cluster RCT, the design of which is described in
detail in Baker et al. (20). In brief, a multicenter prospective,
randomized, open, blinded endpoint design will be utilized to
compare Quitlink against usual smoking care in helping SSMI to
quit smoking. The trial aims to recruit 382 participants with SMI
from participating residential and nonresidential, hospital, and
community-based mental health services in Victoria, Australia.
The trial will entail cluster randomization: where individuals
are part of a short- or long-term residential rehabilitation
program, that residential program will be considered a cluster.
Where individuals are not part of a residential rehabilitation
program, they will be randomized individually, i.e., a cluster
of 1. Participants randomized to the intervention group will
receive the full Quitlink intervention as described below. All
participants will undergo follow-up at 2, 5, and 8 months
postbaseline. The main outcomes are described below in the
section Identification, Measurement, and Valuation of Outcomes
and described in detail in Baker et al. (20). A qualitative study
will investigate the experience of participants with a focus on
further enhancing engagement with the intervention. Full ethics
approval for the methods described here and in Baker et al. (20)
was obtained from the University of Newcastle (H-2018-0192)
and St Vincent’s Hospital, Melbourne (HREC/18/SVHM/154).

Screening, Randomization, and the Usual
Care Control Group

Potential participants will be engaged and screened for
eligibility by a trained mental health peer worker at specialist
mental health services [see Baker et al. (20) for further details].
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For eligible persons, upon provision of informed consent,
a baseline assessment will be undertaken. Following this,
participants will receive a brief smoking cessation intervention
consisting of brief advice and provision of Quit Victoria written
materials that include the Quitline telephone number.
After the provision of this brief smoking cessation
intervention, participants will be randomly allocated to the
control group or the Quitlink intervention group. The control
group will continue with usual care in relation to smoking
cessation support, as provided by their health care team, that is,
no further intervention will be provided by the research team.

comparison with results from other economic evaluations of
preventive health interventions, including smoking cessation
interventions in people with SMI (25, 29, 34). To further aid decisionmakers, cost-effectiveness findings will be presented alongside
descriptive assessments of the acceptability to stakeholders,
feasibility of scaleup, sustainability, and equity implications of
Quitlink implementation to be assessed by the research team in
consultation with participating organizations (34, 35).

The Intervention

The clinical and HRQoL outcomes detailed below will be
collected as part of participant assessments conducted at
baseline, 2 months (= end of treatment), 5 months (= 3 months
posttreatment), and 8 months (= 6 months posttreatment).

Trial-Based Economic Evaluation
Identification, Measurement, and Valuation
of Outcomes

Following randomization, those allocated to the intervention will
be referred to an enhanced quitline call-back service for SSMI
and have the option of receiving up to 8 weeks of NRT (patches,
complemented by an oral form of NRT, to be used as per pack
guidelines). Quitline will proactively contact the participant to
offer up to 8 weeks of telephone smoking cessation counseling
with a dedicated counselor, which will include monitoring of
mental health symptoms, nicotine withdrawal symptoms, and
medication side effects, as well as mood management strategies
that aid cessation.

Health and Health-Related Behavioral Outcomes

METHODS AND ANALYSIS

The primary health outcome will be successful quits at 8 months
postrandomization. A successful quit is defined as 6 months
sustained abstinence, with no relapse of 7 or more days of
continuous smoking, and no reported smoking in the past
week with biochemical verification). Self-reported cigarette
consumption will also be measured and for the purposes of the
economic evaluation, used to assess changes in out of pocket
expenditure associated with Quitlink.

Economic Evaluation Overview

Health-Related Quality of Life

A cost-effectiveness evaluation will be conducted with
incremental cost-effectiveness ratios (ICER) calculated for the
cost (AUD) per person who quits and QALYs gained compared
with usual care from both health care system and limited societal
perspectives. Cost effectiveness will be estimated at 8 months
postrandomization (trial-based evaluation with costs and
outcomes as per the trial). Given that most of the anticipated
benefits associated with smoking cessation will occur well beyond
the trial period (15, 16, 24), downstream costs and benefits will
be estimated via a modeled economic evaluation. Health care
system costs and health and QALY benefits will be estimated over
the life course of study participants and extrapolated to estimate
the cost effectiveness of rolling out Quitlink nationally.
The health care system perspective will be of most relevance
to agencies that are likely to fund scaleup beyond the trial
setting. Data on important personal out-of-pocket impacts of
Quitlink will also be collected and incorporated with the health
care system data to construct the limited societal perspective
analysis. In the Australian setting, cigarettes are highly taxed
(to reduce smoking) and are among the most expensive in the
world, while the population of people with SMI is generally
financially disadvantaged and often marginalized economically
(32, 33). This makes it important to also assess any consequent
financial impacts on study participants as a result of receiving
the Quitlink intervention.
Future costs and benefits will be discounted using an annual
discount rate of 3% in the base-case. Furthermore, annual discount
rates of 0 and 5% will be applied in sensitivity analysis to facilitate

Frontiers in Psychiatry | www.frontiersin.org

Despite common beliefs that smoking cessation might worsen
the mental health symptoms of smokers, some studies indicate
that smoking cessation leads to no worsening and possibly
improvement in mental health and psychological-related quality
of life (36). It is also plausible that mood and mental well-being
symptoms may change over time, e.g., deteriorate in the short
term while quitting (e.g., first few weeks), and improve after that
(e.g., months after successfully quitting) (36). To explore this,
HRQoL data will be collected using the Assessment of Quality
of Life-8 Dimension (AQoL-8D) instrument at baseline and
follow-up observations at 2, 5, and 8 months. The AQoL-8D is a
preference-based HRQoL instrument which enables calculation
of QALYs experienced across the two study arms. Data from all
time points will be plotted for both arms, and the difference in
areas under the respective curves will be calculated. While the
majority of benefit of this preventive intervention are expected
in the future and a priori expectations of measurable change in
HRQoL during the trial period are modest, among preferencebased HRQoL instruments, the AQoL-8D is considered relatively
sensitive to changes in psychosocial dimensions of HRQoL
(while also capturing important changes in other dimensions of
HRQoL) (37). This means that it will be more likely to identify
smaller changes in mental-health-related quality of life than
other preference-based instruments.

Financial Stress

Respondents will be asked a short module of questions relating to
their financial stress at baseline and follow-up observations (38).

4

September 2019 | Volume 10 | Article 618

Sweeney et al.

Protocol for an Economic Evaluation of the Quitlink RCT

For example, have they foregone meals; asked for financial help;
or been unable to pay electricity, gas, or telephone bills because
of a lack of money (see online Appendix to view questions)?
This will provide further evidence for decision-makers and
mental health and smoking program organizations regarding
potential financial impacts of Quitlink on this financially
disadvantaged population (32).

to estimate costs from a limited societal perspective. These costs
will include out-of-pocket co-payments associated with drug
and health service utilization, expenditure on cigarettes, and
cessation aids purchased in addition to those provided as part
of the intervention, as well as time costs and productivity losses
associated with absenteeism from paid and unpaid work and
productive activities (see online Appendix to view questions).
Where data relies on respondent recall, for example, number
of allied health visits or cigarettes smoked, the recall period
will be deliberately kept relatively short (1 month and 1 week,
respectively). Recall bias may remain an issue though, so the
potential impact of this will be tested in sensitivity analyses (39).
In general, a simple extrapolation rule will be followed where
reported rates are applied for the full period since previous
follow-up, where appropriately justified.
One-off costs for products which could be used in other
settings, such as costs of developing the training and intervention
materials, will be excluded. The costs and health implications
from passive smoking will also be excluded.

Identification and Measurement of Costs

Table 1 summarizes the costs included and the data collection
strategy from both a health sector and societal perspective. Costs
included from the health care system perspective will include
direct intervention costs (e.g., opportunity cost of Quitline and
peer worker staff, telephone calls, NRT) for both Quitlink and
usual care, as well as drug and health service utilization costs.
Pathway analysis will be undertaken to ensure all relevant
costs are identified. These data will be collected from project
administrative records, respondent surveys (baseline, 2, 5, and
8 months) and with participant consent, linked data on their
service and prescription medication use from the Australian
Government subsidized Medicare (MBS) and Pharmaceutical
Benefits (PBS) schemes, which are predominantly out-ofhospital resource use.
Data on important out-of-pocket impacts of Quitlink will also
be collected and incorporated with the health care system data

Valuing Costs

All resource use will be costed using nationally published
reference costs or market prices where appropriate. Personnel
time (paid, unpaid, volunteer time) will be costed using
opportunity cost principles, where volunteer/leisure time

TABLE 1 | Costs included in trial-based cost-effectiveness analyses.
Cost category

Costs

Direct intervention costs

Costs associated with training of peer workers
and Quitline staff, including personnel time
(facilitators and participants), venue/catering,
printing/stationery.
Personnel time for intervention delivery: Quitline
and peer worker support time spent per
study participant in both Quitlink and usual
care arms. Costs of telephone calls. Program
management time.
On-costs will be included.

HS & S

Project administrative records.

HS & S

Project administrative records and
administrative data provided by
participating organizations.

Hospitalizations (including length of
stay) and other intensive health services,
including ED and community care units
(CCUs) and prevention and recovery care
services (PARCS).

HS & S

Respondent surveys.

Community-based (noninpatient) government
subsidized health (including mental
health) services.

HS & S

Linkage to Australian Department of Human
Services data on Medicare and PBS use.
Literature review.

Allied health services (nonsubsidized) including
(non-Quitline) counseling, acupuncture,
hypnotherapy, group therapies.
e.g., patches, gum, lozenges, inhalator,
sprays, e-cigarettes.
Including varenicline, bupropion,
psychotropic medicines.

S

Respondent surveys.

HS & S

Respondent surveys.

HS & S

Australian Department of Human Services
data on Medicare and PBS use,
literature review.
Respondent surveys.
Respondent surveys.
Project records on session numbers
and duration.

Health service utilization

Nicotine replacement therapies and other
quitting aids
Medicines

Cigarettes
Productivity losses and gains

Perspective

Cost of cigarette purchases.
Absenteeism from paid and unpaid work
(e.g., volunteering, study, caring).
Potential increases in employment.

S
S

Collection strategy

HS, Health care system; S, societal; ED, emergency department; PBS, Pharmaceutical Benefits Scheme.

Frontiers in Psychiatry | www.frontiersin.org
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will be valued at 25% of appropriate average wage rates (34).
Resource use of nonhealth sector goods and services will be
valued at market prices and be informed by best available
evidence from Australian-based studies. Where relevant, health
resources will be costed as per the Manual of Resource Items
for use in submissions to the Commonwealth of Australia’s
Pharmaceutical Benefits Advisory Committee (40). Health
care cost information will also be drawn from the Australian
Institute of Health and Welfare (AIHW) health care cost data.
All costs will be inflated to current Australian dollars for the
year of study completion (2022) using the all-items Consumer
Price Index from the Australian Bureau of Statistics.

evidence and suitability of including a suicidal health state
in the Markov model and suicide as an additional smokingrelated cause of death.
The trial cohort at the end of the trial follow-up will enter
the Markov model as either a healthy smoker or healthy
ex-smoker (i.e., successful quitter), where “healthy” means
they have not had a stroke, MI, or developed COPD or lung
cancer. Their commencement QALY weight in the model
will be their final observed QALY weight from the trial (i.e.,
8-month follow-up). Individuals will be modeled through
annual cycles. In the first cycle, people have a probability of
either remaining a healthy smoker or ex-smoker, relapsing
from healthy ex-smoker to healthy smoker, experiencing a
fatal or nonfatal MI, stroke, COPD, lung cancer, or entering
a severe psychiatric episodic health state (e.g., psychiatric
hospitalization and/or suicide attempt), or they may die from
another cause.
Each health transition and health state incurs associated
treatment/management costs. Associated health costs and risk of
disease-related mortality can differ over time since initial episode/
diagnosis (41). The Markov cycles will continue until the entire
cohort has either died or reached aged 85 years (41). The same
model structure will be used to estimate the broader benefits and
cost savings of scaling up Quitlink to a larger population cohort of
people with SMI.
Existing evidence for transition probabilities for the
different disease states and utility weights attached to life
lived with those health states used in Hurley et al. (41) and
Godfrey et al. (24) will be considered for use in this model,
subject to an updated literature search. Smoking relapse rates
will be estimated using the large longitudinal Household
Income Labour Dynamics in Australia (HILDA) survey data.
Specifically, relapse rates of data for people who self-report
poor mental-health-related quality of life in the early HILDA
waves on the included Short Form-12 item (SF-12) instrument
will be analyzed.
The longer term health care system costs incurred by the
two intervention arms will comprise actual health care resource
usage obtained from the government subsidized MBS and PBS
database (which will provide data of up to 4 years for the early
study enrolments) and health care cost information from the
Australian Institute of Health and Welfare (AIHW)—to estimate
costs of acute and ongoing management associated with the
stated main model health states. Where there is potential for
double counting across the two data sources, conservative
inclusion decisions will be made.
Where transition rate, utility weight, and health cost data
are available specifically for people living with SMI (and if
possible, in Australia), it will be used to populate the model.
Given that most of such data are currently unavailable, data
from general population studies will be employed, coupled
with a discussion on how the likely cost effectiveness of
Quitlink may be impacted. All model parameters will be
subject to an updated literature search at the end-point of the
clinical trial to identify if potentially more suitable model data
have become available.

Modeling Long-Term Cost Effectiveness

A decision analytic Markov model will be developed using
TreeAge software to estimate the future benefits and cost
savings arising from any increase in successful quits observed
in the Quitlink arm. We will adapt and update the smoking
cessation model developed with an Australian context by
Hurley et al. (41). The model projects the future smoking status
of the population where smoking status impacts on the risk of
experiencing (progressing into the following health states)—
myocardial infarction (MI), stroke, COPD, or lung cancer.
These four health states are known to have the largest disease,
mortality, and health cost burden among smokers (41). For
simplicity, the model does not include the potential for comorbid
health states where a person may have more than one of these
four states concurrently. Death following transition into one of
these diagnosed health states can be caused by that condition
or any other cause. “Healthy” smokers and ex-smokers can
also die from other causes without experiencing these health
states. This approach is intentionally conservative (i.e., it likely
underestimates the benefits of quitting) and has been taken in a
number of smoking models (24).
We plan to extend the Hurley and Matthews (41) model.
Figure 1 depicts the potential health states that the modeled
Quitlink cohort will face over repeat model annual cycles.
Given smokers with SMI (compared to ex-smokers with SMI)
face increased risk of hospitalization for a psychiatric episode,
a psychiatric episodic health state will be added to the model to
capture the costs related to hospitalizations and the impact on
QALYs (12). QALY weights for the psychiatric episodic health
state will be obtained where possible, from the literature or
by expert opinion, guided by the AQoL-8D questionnaire. In
the model, we will also consider that smoking cessation may
reduce suicide risk—attempts and, more rarely, deaths (42,
43). Uncertainty remains around this mechanism of action.
However, the known links between smoking and reduced
effectiveness of antipsychotic medication, and between
smoking cessation and mood improvement, suggest that
any increased smoking cessation achieved by Quitlink may
plausibly reduce suicide attempts and deaths—especially if the
program was scaled up. A review of the literature of the causal
link between smoking and suicidality will be undertaken
at the end of the trial period to determine the strength of
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FIGURE 1 | State transitions for Markov Model. COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; yr 1, first year in a given health state;
yr > 1, subsequent years lived in a given health state.

Uncertainty and Scenario Analyses

a discussion of model validity, comparing results with those of
other smoking cessation models including those reported in the
literature review by (24).

All analyses in both the trial-based cost-efficacy and modeled
cost-effectiveness evaluations will be subjected to both oneway and probabilistic sensitivity analysis where the impacts
of plausible variation in data parameters will be tested, using
confidence intervals around for example, utility weights, and
health costs associated with different health states. This will
provide an understanding of which values or assumptions
are associated with the greatest amount of uncertainty. As
previously mentioned, by necessity, some model parameters
will be populated with data from the general population, rather
than specifically people with SMI. Given this, scenario analyses
will be conducted to investigate the impact of SMI-related
data adjustments, which expert opinion suggests is, prima
facie appropriate, where there is only poor quality or no data
available for a given parameter to test uncertainty. These will
include, for example, different transition risks and lower utility
scores attached to health states for people with SMI compared
with general population data used, as well as uncertainty
around treatment costs for the main modeled health states for
people with SMI. These analyses will also enable estimates of
the probability that Quitlink is cost effective to aid funding
decision-makers in light of such model uncertainty.
Results of a number of sensitivity tests will be reported
on a cost-effectiveness plane and as acceptability curves. The
Australian Government has no explicit threshold for what it
considers cost effective; however, there exists implicit evidence
that the Pharmaceutical Benefits Advisory Committee view
interventions that achieve an incremental cost effectiveness ratio
(ICER) of no more than AUD45,000 per additional QALY gained,
as cost effective (44). This threshold will be applied for the costeffective acceptability analysis. Published results will include
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DISCUSSION
This protocol sets out a plan to assess the cost effectiveness of
Quitlink versus usual care via both trial-based and modeled
economic evaluations. The publication of this protocol has two
purposes. First, we aim to inform the research and broader public
health communities of the conduct of this economic evaluation
alongside the Quitlink trial. Second, we set out the plan for analyses
a priori, thereby reducing potential biases made from ad hoc analytic
decisions. Any deviations from this protocol will be described and
justified in final analyses. In the event that no significant difference is
found for the primary outcome, the described economic evaluation
may be undertaken where there is a) significant change in key
secondary outcomes (QALYs or number of cigarettes smoked)
or b) compelling evidence suggesting the sample lacked power or
insufficient follow-up to detect a likely significant difference. While
we are setting out to identify and collect the best available data to
establish the cost effectiveness of Quitlink, there are a number of
potential limitations. The exclusion of so-called second-hand (or
passive) smoking effects may result in an underestimation of the
true benefits to the health care system and broader society as a
result of any observed Quitlink treatment effect. For the trial-based
evaluation, there is a risk of recall bias in the respondent surveys,
relating to—among other data—health service use, medications
used, NRTs, and cigarettes purchased. To minimize this potential
bias, actual health and medication use data will be obtained from
Australian Government MBS and PBS schemes. Further, in the
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respondent surveys, the recall period that participants will be asked
to consider will be deliberately kept short. A further potential risk
to data reliability relates to HRQoL. While the AQoL-8D has been
shown to be more sensitive to changes in people’s mental health
than other instruments (37), there is a risk that the sample size and
duration may be insufficient to identify the expected small changes
in mental-health-related quality of life within the trial period.
The a priori expectation for benefits to largely occur well
beyond the trial period (as has been largely demonstrated for
smoking cessation interventions) justifies the decision to model
future benefits and costs. However, the model-based analyses
also carry a number of potential limitations. For the sake of
transparency, a Markov model structure has been proposed that
includes only a limited number of the full range of smokingrelated health states experienced by current and past smokers
(24, 25) concentrating on the health and health system impacts
of MI, stroke, COPD, lung cancer, and psychotic-related
hospitalizations. While these conditions are responsible for an
estimated 80% of the diseases and economic burden associated
with smoking morbidity and mortality in the Australian setting,
there are other smoking-related health issues which will not
be included (41). Should Quitlink be found to be effective, the
exclusion of other diseases from the model underestimates the
true cost effectiveness of Quitlink. Furthermore, it is anticipated
that much of the data for the smoking cessation modeling will
come from the general population estimates; such data may not
reflect the utilities or health costs or transition risks of people
with SMI. An updated literature review for all parameters will be
conducted at the end of the trial period to ensure up to date and
relevant data is used for all model parameters.
Smoking places significant additional financial burden
on people with SMI, a particularly financially vulnerable
subpopulation. Any financial implications for people with SMI,
seen through changes in cigarette consumption, out of pocket
costs of health resource utilization and productivity will be
presented, providing valuable information on the equity impacts
of Quitlink. This research project will conduct analyses and
present results of most relevance to smoking cessation program
designers and health-funding decision makers. Quitlink has been
designed for and will be trialed in a setting where Quitline and
mental health peer workers are established parts of the health
sector. The cost-effectiveness findings may not be generalizable
to settings where such foundations for Quitlink are not in place.

(with and without NRT) has been well established in general
populations; however, there is little evidence of cost effectiveness
for such interventions that specifically target SSMI. Furthermore,
evidence suggests that SSMI are less likely to be referred to
quitlines. The Quitlink intervention, therefore, aims to bridge this
gap. Quitlink utilizes existing mental health peer workforce to
link SSMI with a tailored quitline service for SSMI. The research
team hypothesizes that the use of these existing workforces and
tailored quitline support for SSMI will result in Quitlink being
found to be both effective and cost effective and also scalable.

CONCLUSION
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